Literature DB >> 19965927

Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women.

Michael T Yin1, Don J McMahon, David C Ferris, Chiyuan A Zhang, Aimee Shu, Ronald Staron, Ivelisse Colon, Jeffrey Laurence, Jay F Dobkin, Scott M Hammer, Elizabeth Shane.   

Abstract

CONTEXT: Low bone mineral density (BMD) is commonly reported in young men and women with HIV infection, and fracture rates may be higher. With effective antiretroviral therapy (ART), the HIV population is aging. However, little is known about the skeletal status of postmenopausal women.
OBJECTIVE: We aimed to assess the effects of HIV infection and ART on BMD and bone turnover in postmenopausal minority women. DESIGN, SETTING, AND PATIENTS: A prospective cohort study was performed in 92 HIV+ and 95 HIV- postmenopausal Hispanic and African-American women. MAIN OUTCOME MEASURES: We measured BMD by dual-energy x-ray absorptiometry, fracture prevalence, serum levels of inflammatory cytokines (TNFalpha, IL-6), bone turnover markers, calciotropic hormones, and estrone.
RESULTS: HIV+ women were younger (56 +/- 1 vs. 60 +/- 1 yr; P < 0.01) and had lower BMI (28 +/- 1 vs. 30 +/- 1 kg/m(2); P < 0.01) and estrone levels. Prevalence of T scores below -1.0 was greater in HIV+ women at the spine (78 vs. 64%; P < 0.05), total hip (45 vs. 29%; P < 0.05), and femoral neck (64 vs. 46%; P < 0.05), and Z scores adjusted for BMI were lower in HIV+ women at the same sites. Serum TNFalpha, N-telopeptide, and C-telopeptide were significantly higher in HIV+ than HIV- women, particularly those receiving ART. HIV+ status was independently and negatively associated with spine and hip BMD after adjustment for age, ethnicity, BMI, and alcohol.
CONCLUSION: The lower BMD, higher prevalence of low BMD, and higher levels of bone turnover markers detected in HIV+ postmenopausal minority women could place them at high risk for future fractures.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965927      PMCID: PMC2840861          DOI: 10.1210/jc.2009-0708

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  32 in total

1.  Osteopenia in HIV-infected patients: is it the disease or is it the treatment?

Authors:  H Knobel; A Guelar; G Vallecillo; X Nogués; A Díez
Journal:  AIDS       Date:  2001-04-13       Impact factor: 4.177

2.  Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy.

Authors:  P Tebas; W G Powderly; S Claxton; D Marin; W Tantisiriwat; S L Teitelbaum; K E Yarasheski
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

3.  Select HIV protease inhibitors alter bone and fat metabolism ex vivo.

Authors:  Renu G Jain; James M Lenhard
Journal:  J Biol Chem       Date:  2002-04-05       Impact factor: 5.157

4.  Osteopenia in eugonadal men with acquired immune deficiency syndrome wasting syndrome.

Authors:  W P Fairfield; J S Finkelstein; A Klibanski; S K Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

5.  HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk.

Authors:  J Mohamad Fakruddin; Jeffrey Laurence
Journal:  J Biol Chem       Date:  2003-09-15       Impact factor: 5.157

6.  Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy.

Authors:  Dario Bruera; Norma Luna; Daniel O David; Liliana M Bergoglio; Javier Zamudio
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

Review 7.  Diagnosis of osteoporosis and assessment of fracture risk.

Authors:  John A Kanis
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

8.  Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals.

Authors:  Kristin Mondy; Kevin Yarasheski; William G Powderly; Michael Whyte; Sherry Claxton; Debra DeMarco; Mary Hoffmann; Pablo Tebas
Journal:  Clin Infect Dis       Date:  2003-01-29       Impact factor: 9.079

9.  Osteopenia in HIV-infected women prior to highly active antiretroviral therapy.

Authors:  J Teichmann; E Stephan; U Lange; T Discher; G Friese; J Lohmeyer; H Stracke; R G Bretzel
Journal:  J Infect       Date:  2003-05       Impact factor: 6.072

10.  Altered bone metabolism in children infected with human immunodeficiency virus.

Authors:  G Zamboni; F Antoniazzi; F Bertoldo; S Lauriola; L Antozzi; L Tatò
Journal:  Acta Paediatr       Date:  2003       Impact factor: 2.299

View more
  42 in total

1.  Bone disease in HIV infection.

Authors:  Maristella Francesca Saccomanno; Adriana Ammassari
Journal:  Clin Cases Miner Bone Metab       Date:  2011-01

2.  Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women.

Authors:  E M Stein; M T Yin; D J McMahon; A Shu; C A Zhang; D C Ferris; I Colon; J F Dobkin; S M Hammer; E Shane
Journal:  Osteoporos Int       Date:  2010-06-29       Impact factor: 4.507

3.  Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats.

Authors:  Tatyana Vikulina; Xian Fan; Masayoshi Yamaguchi; Susanne Roser-Page; Majd Zayzafoon; David M Guidot; Ighovwerha Ofotokun; M Neale Weitzmann
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

Review 4.  Care of the human immunodeficiency virus-infected menopausal woman.

Authors:  Helen Elizabeth Cejtin
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

5.  Bone alterations associated with HIV.

Authors:  Amy H Warriner; Michael Mugavero; E Turner Overton
Journal:  Curr HIV/AIDS Rep       Date:  2014-09       Impact factor: 5.071

6.  Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density.

Authors:  J Natsag; M A Kendall; D E Sellmeyer; G A McComsey; T T Brown
Journal:  HIV Med       Date:  2015-07-16       Impact factor: 3.180

7.  Bone mineral density in children and adolescents with perinatal HIV infection.

Authors:  Linda A DiMeglio; JiaJia Wang; George K Siberry; Tracie L Miller; Mitchell E Geffner; Rohan Hazra; William Borkowsky; Janet S Chen; Laurie Dooley; Kunjal Patel; Russell B van Dyke; Roger A Fielding; Yared Gurmu; Denise L Jacobson
Journal:  AIDS       Date:  2013-01-14       Impact factor: 4.177

8.  Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy.

Authors:  Kristine M Erlandson; Maryann OʼRiordan; Danielle Labbato; Grace A McComsey
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

9.  Bilateral sub-trochanteric femur fragility fractures in a patient on antiretroviral therapy: a case based discussion and review of literature.

Authors:  Rajesh K Rajnish; Pratik M Rathod; Sameer Aggarwal; Saurabh Agarwal; Prasoon Kumar
Journal:  Int J Burns Trauma       Date:  2020-08-15

10.  Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women.

Authors:  Vincent Lo Re; Kenneth Lynn; Emily R Stumm; Jin Long; Melissa S Nezamzadeh; Joshua F Baker; Andrew N Hoofnagle; Angela J Kapalko; Karam Mounzer; Babette S Zemel; Pablo Tebas; Jay R Kostman; Mary B Leonard
Journal:  J Infect Dis       Date:  2015-03-09       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.